One patient (64-year-old woman) with NOTCH1-activated metastatic ACC and tumor BCL2 overexpression had SD to CB-103 (250 mg twice daily) for 3 months, and upon signs of disease progression off-label Venetoclax (BCL2 inhibitor) was added to CB-103 resulting in further disease stabilization for an additional 3.5 months, with good tolerance in combination. The gene discussed is BCL2; the disease is neoplasm.